Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Biotech-Perle kurz vor entscheidender Meilenstein-Meldung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 852738 | ISIN: BE0003739530 | Ticker-Symbol: UNC
Tradegate
16.04.24
17:58 Uhr
119,40 Euro
+0,70
+0,59 %
1-Jahres-Chart
UCB SA Chart 1 Jahr
5-Tage-Chart
UCB SA 5-Tage-Chart
RealtimeGeldBriefZeit
119,00120,2018:44
119,45119,5518:44

Aktuelle News zur UCB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.UCB: FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations146Application in moderate-to-severe hidradenitis suppurativa based on results from two Phase 3 studies where BIMZELX® (bimekizumab-bkzx) showed clinically meaningful improvements vs. placebo at Week...
► Artikel lesen
25.03.'New launches on track', Morgan Stanley ups UCB to 'equal weight'14
22.03.UCB's Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults7
22.03.UCB Convening Notice to the General Meeting of the Shareholders 2024318CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the ordinary and extraordinary general meeting of the shareholders (the "General Meeting"...
► Artikel lesen
18.03.UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis7
12.03.UCB presents positive long-term results for bimekizumab in hidradenitis suppurativa5
09.03.UCB's BIMZELX Demonstrates Sustained Complete Skin Clearance In Moderate-to-Severe Plaque Psoriasis4
08.03.UCB: BIMZELX 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count387Patients treated with BIMZELX® (bimekizumab-bkzx) demonstrated clinically meaningful improvements in skin pain up to 48 weeks, across various assessed outcomes At Week 16, patients treated with BIMZELX...
► Artikel lesen
08.03.MHRA approves UCB's Rystiggo to treat generalised myasthenia gravis3
07.03.UCB ups the ante with CDMO Samsung Biologics, signing $353M deal2
07.03.Samsung Biologics Signs Contract Worth 381.9 Billion Won with UCB for Contract Manufacturing3
06.03.Samsung Biologics inks $352.7 mln deal with Belgium-based UCB4
06.03.Samsung Biologics clinches $352 million deal with Belgium's UCB6
28.02.UCB SA reports FY results11
28.02.Seeking blockbuster status, UCB eyes four new indications for psoriasis med Bimzelx in 202412
28.02.UCB on Growth Path for a Decade Plus613Revenue in 2023 reached € 5.25 billion (-5%; -6% CER1), net sales were € 4.87 billion (-5%; -6% CER1) - in-line with financial guidance Strong performance by newly launched growth drivers (net sales...
► Artikel lesen
28.02.UCB rises after full-year sales beat11
16.02.UCB presents positive phase 3 results for bimekizumab in hidradenitis suppurativa12
05.02.J&J's $6.5B autoimmune drug hits phase 3 goal, teeing up approval talks and keeping heat on argenx, UCB17
31.01.Jefferies sees higher peak sales for UCB's Bimzelx, ups to 'buy'17
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2